344 related articles for article (PubMed ID: 10866357)
1. Peptides and antitumor activity. Development and investigation of some peptides with antitumor activity.
Teplán I
Acta Biol Hung; 2000; 51(1):1-29. PubMed ID: 10866357
[TBL] [Abstract][Full Text] [Related]
2. Effect of gonadotropin-releasing hormone analogs and their conjugates on gonadotropin-releasing hormone receptor--positive human cancer cell lines.
Pályi I; Vincze B; Kálnay A; Turi G; Mezõ I; Teplán I; Seprõdi J; Pató J; Móra M
Cancer Detect Prev; 1996; 20(2):146-52. PubMed ID: 8706040
[TBL] [Abstract][Full Text] [Related]
3. Continuous administration of the somatostatin structural derivative /TT-232/ by subcutaneously implanted osmotic pump improves the efficacy and potency of antitumor therapy in different mouse and human tumor models.
Tejeda M; Gaal D; Hullán L; Csuka O; Schwab R; Szokoloczi O; Kéri GY
Anticancer Res; 2008; 28(5A):2769-74. PubMed ID: 19035308
[TBL] [Abstract][Full Text] [Related]
4. The antitumor activity of the somatostatin structural derivative (TT-232) on different human tumor xenografts.
Tejeda M; Gaal D; Barna K; Csuka O; Kéri G
Anticancer Res; 2003; 23(5A):4061-6. PubMed ID: 14666719
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of the somatostatin structural derivative (TT-232), against mouse and human melanoma tumor models.
Tejeda M; Gaál D; Hullán L; Schwab R; Szokoloczi O; Kéri G
Anticancer Res; 2007; 27(6B):4015-9. PubMed ID: 18225564
[TBL] [Abstract][Full Text] [Related]
6. In vivo studies of the new gonadotropin-releasing hormone antagonist--copolymer conjugates having antitumor activity.
Vincze B; Pályi I; Gaál D; Pató J; Móra M; Mezõ I; Teplán I; Seprõdi J
Cancer Detect Prev; 1996; 20(2):153-9. PubMed ID: 8706041
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationship studies of novel somatostatin analogs with antitumor activity.
Kéri G; Mezô I; Vadász Z; Horváth A; Idei M; Vántus T; Balogh A; Bökönyi G; Bajor T; Teplán I
Pept Res; 1993; 6(5):281-8. PubMed ID: 7903057
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of gonadotropin-releasing hormone III analogs. Structure-antitumor activity relationships.
Mezö I; Lovas S; Pályi I; Vincze B; Kálnay A; Turi G; Vadász Z; Seprödi J; Idei M; Tóth G; Gulyás E; Otvös F; Mák M; Horváth JE; Teplán I; Murphy RF
J Med Chem; 1997 Oct; 40(21):3353-8. PubMed ID: 9341910
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effect of GnRH agonist in epithelial ovarian cancer.
Kim JH; Park DC; Kim JW; Choi YK; Lew YO; Kim DH; Jung JK; Lim YA; Namkoong SE
Gynecol Oncol; 1999 Aug; 74(2):170-80. PubMed ID: 10419728
[TBL] [Abstract][Full Text] [Related]
10. Is lGnRH-III the most potent GnRH analog containing only natural amino acids that specifically inhibits the growth of human breast cancer cells?
Herédi-Szabó K; Murphy RF; Lovas S
J Pept Sci; 2006 Nov; 12(11):714-20. PubMed ID: 16967433
[TBL] [Abstract][Full Text] [Related]
11. Novel antitumor peptide hormones and their effect on signal transduction.
Kéri G; Balogh A; Horváth A; Mezö I; Vadász Z; Bökönyi G; Bajor T; Vántus T; Teplán I; Horváth J
J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):105-10. PubMed ID: 1356011
[TBL] [Abstract][Full Text] [Related]
12. Effects of GnRH analogs on six ovarian cancer cell lines in culture.
Connor JP; Buller RE; Conn PM
Gynecol Oncol; 1994 Jul; 54(1):80-6. PubMed ID: 8020844
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of GnRH analogs having direct antitumor and low LH-releasing activity.
Mezô I; Seprôdi J; Vincze B; Pályi I; Kéri G; Vadász Z; Tóth G; Kovács M; Koppán M; Horváth JE; Kálnay A; Teplán I
Biomed Pept Proteins Nucleic Acids; 1996; 2(2):33-40. PubMed ID: 9346824
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts.
Chen P; Cameron R; Wang J; Vallis KA; Reilly RM
J Nucl Med; 2003 Sep; 44(9):1469-78. PubMed ID: 12960194
[TBL] [Abstract][Full Text] [Related]
15. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, conformation, biodistribution, and hormone-related in vitro antitumor activity of a gonadotropin-releasing hormone antagonist-branched polypeptide conjugate.
Mezö G; Mezö I; Pimm MV; Kajtár J; Seprödi J; Teplán I; Kovács M; Vincze B; Pályi I; Idei M; Szekerke M; Hudecz F
Bioconjug Chem; 1996; 7(6):642-50. PubMed ID: 8950483
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the antitumor efficacy of the somatostatin structural derivative TT-232 on different tumor models.
Tejeda M; Gaál D; Hullán L; Hegymegi-Barakonyi B; Kéri G
Anticancer Res; 2006; 26(5A):3477-83. PubMed ID: 17094470
[TBL] [Abstract][Full Text] [Related]
18. Novel heptapeptide somatostatin analog displays anti-tumor activity independent of effects on growth hormone secretion.
Murphy WA; Taylor JE; Moreau JP; Coy DH
Pept Res; 1989; 2(1):128-32. PubMed ID: 2577697
[TBL] [Abstract][Full Text] [Related]
19. Indirect antiproliferative effect of the somatostatin analog octreotide on MIA PaCa-2 human pancreatic carcinoma in nude mice.
Weckbecker G; Raulf F; Bodmer D; Bruns C
Yale J Biol Med; 1997; 70(5-6):549-54. PubMed ID: 9825482
[TBL] [Abstract][Full Text] [Related]
20. Direct inhibiting effects of [D-Trp6]gonadotropin-releasing hormone on the estrogen-sensitive progression of polyoma virus-induced mammary tumors in athymic mice.
Néri C; Blangy D; Schatz B; Drieu K; Berebbi M; Martin PM
Cancer Res; 1990 Sep; 50(18):5892-7. PubMed ID: 2168284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
